Recent advances in osteoclast biology and pathological bone resorption

Histology and Histopathology

Volumn 19, Issue 1, 2004, Pages 189-199

  Blair, H C ^a   Athanasou, N A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CAII; CLIC5; M CSF; Vitamin D

Indexed keywords

CALCITRIOL; CARBONATE DEHYDRATASE II; CARRIER PROTEIN; CATHEPSIN K; CHLORIDE CHANNEL; COLONY STIMULATING FACTOR 1; CYTOKINE; ENZYME; ESTRADIOL; GLUCOCORTICOID; HUMORAL ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; THIOL PROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ALBERS SCHOENBERG DISEASE; ARTHRITIS; BONE DISEASE; BONE MATRIX; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CELL DIFFERENTIATION; CELL LINEAGE; CYTOLOGY; DISSOLUTION; DYSOSTOSIS; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; MACROPHAGE; MESENCHYME CELL; MONOCYTE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BONE RESORPTION; CALCITRIOL; CELL DIFFERENTIATION; CYTOKINES; GLYCOPROTEINS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MODELS, BIOLOGICAL; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 1642433325     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Alper S.L. (2002). Genetic diseases of acid-base transporters. Annu. Rev. Physiol. 64, 899-923.
2. Alvarez J.I., Teitelbaum S.L., Blair H.C., Greenfield EM., Athanasou N.A. and Ross F.P. (1991). Generation of avian cells with the osteoclast phenotype from mononuclear phagocytes. Endocrinology 128, 2324-2335.
3. Akiyama H., Shigeno C., Iyama K., Ito H., Hiraki Y., Konishi J. and Nakamura T. (1999). Indian hedgehog in the late-phase differentiation in mouse chondrogenic EC cells, ATDC5: Upregulation of type X collagen and osteoprotegerin ligand mRNAs. Biochem. Biophys. Res. Commun. 257, 814-820.
4. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D. and Galibert L. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
5. Athanasou N.A. and Quinn J. (1990). Immunophenotypic differences between osteoclasts and macrophage polykaryons: Immunohistological distinction and implications for osteoclast ontogeny and function. J. Clin. Pathol. 43, 997-1003.
6. Atkins G.J., Haynes D.R., Geary S.M., Loric M., Crotti T.N. and Findlay D. (2000). Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone 26, 653-661.
7. Bessis N., Guery L., Mantovani A., Vecchi A., Sims J.E., Fradelizi D. and Boissier M.C. (2000). The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur. J. Immunol. 30, 867-875.
8. Blair H.C., Julian B.A., Cao X., Jordon S.E and Dong S.S. (1999). Parathyroid hormone-regulated production of c-kit ligand in human osteoblasts and osteoblast-like cells. Biochem. Biopshys. Res. Commun. 255, 778-784.
9. Blair H.C. and Schlesinger P.H. (1990). Purification of a stilbene sensitive chloride channel and reconstitution of chloride conductivity into phospholipid vesicles. Biochem. Biophys. Res. Commun. 171, 920-925
10. Blair H.C., Teitelbaum S.L., Ghiselli R. and Gluck S. (1989). Osteoclastic bone resorption by polarized vacuolar proton pump. Science 245, 855-857.
11. +-ATPase of avian osteoclast ruffled membrane. Am. J. Physiol. 260, C1315-C1324.
12. Brandstrom H., Bjorkman T. and Ljunggren O. (2001). Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem. Biophys. Res. Commun. 280, 831-835.
13. Brandt S. and Jentsch T.J. (1995). CIC-6 and CIC-7 are two novel broadly expressed members of the CLC chloride channel family. FEBS Lett. 377, 15-20.
14. Cao L., Bu R., Oakldy J.I., Kalla S.E. and Blair H.C. (2003). Estrogen receptor-β modifies expression of matrix proteins in human MG63 osteosarcoma cells. J. Cell Biochem. 89, 152-164.
15. Carano A., Teitelbaum S.L., Konsek J.D., Schlesinger P.H. and Blair H.C. (1990). Biophosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 85, 456-461.
16. Carn G., Koller D.L, Peacock M., Hui S.L., Evans W.E., Conneally P.M., Johnston C.C. Jr, Foroud T. and Econs M.J. (2002). Sibling pair linkage and association studies between peak bone mineral density and the gene locus for the osteoclast-specific subunit (OC116) of the vacuolar proton pump on chromosome 11p12-13. J. Clin. Endocrinol. Metab. 87, 3819-3824.
17. Chung H., Kang Y.S., Hwang C.S., Moon I.K., Yim C.H., Choi K.H., Han K.O., Jang H.C., Yoon H.K. and Han I.K. (2001). Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. J. Korean Med. Sci. 16, 769-773.
18. Chung J.Y., Park Y.C., Ye H. and Wu H. (2002). All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 115, 679-688.
19. Cleiren E. (2001). Albers-Schonberg disease (autosomal dominant osoteopetrosis, type II) results from mutations in the CICN7 chloride channel gene. Hum. Mol. Genet. 10, 2861-2867.
20. Cutolo M., Sulli A., Barone A., Seriolo B. and Accardo S. (1993). Macrophages, synovial tissue and rheumatoid arthritis. Clin. Exp. Rheumatol. 11, 331-339.
21. Diewald L., Rupp J., Dreger M., Hucho F., Gillen C. and Nawrath H. (2002). Activation by acidic pH of CLC-7 expressed in oocytes from Xenopus laevis. Biochem. Biophys, Res, Commun. 291, 421-424.
22. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J, Tometsko M.E, Maliszewski C.R., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P.J., Peschon J.J. and Schuh J. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424.
23. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.S., James I.E., Rosenberg M., Lee J.C. and Young P.R. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
24. Faust Lacey D.L, Hunt P., Burgess T.L, Scully S., Van G., Eli A., Qian Y. and Shalhoud V. (1999). Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J. Cell Biochem. 72, 67-80.
25. Feuerherm A.J., Borset M., Seidel C., Sundan A., Leistad L., Ostensen M. and Faxvaag A. (2001). Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand. J. Rheumatol. 30, 229-234.
26. Frattini A., Orchard P.J., Sobacchi C., Giliani S., Abinun M., Mattsson J.P., Keeling D.J., Andersson A.K., Wallbrandt P., Zecca L., Notarangelo L.D., Vezzoni P. and Villa A. (2000). Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nature Genet. 25, 343-346
27. Fujikawa Y., Quinn J.M., Sabokbar A., McGee J.O. and Athanasou N.A. (1996). The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137, 4058-4060.
28. Gattei V., Aldinucci D., Quinn J.M., Degan M., Cozzi M., Perin V., Luliis A.D., Juzbasic S., Improta S., Athanasou N.A., Ashman L.K. and Pinto A. (1996). Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane bound stem cell factor. Cell Growth Diff. 7, 753-763.
29. Gelb B.D., Shi G.P., Chapman H.A. and Desnick R.J. (1996). Pycnodoysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273, 1236-1238.
30. Grano M., Galimi F., Zambonin G., Colucci S., Cottone E., Zallone A.Z. and Comoglio P.M. (1996). Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc. Nat. Acad. Sci. USA 93, 7644-7648.
31. Horwood N.J., Elliott J., Martin T.J. and Gillespie M.T. (2001). Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139, 4743-4746.
32. Haynes D.R., Barg E., Crotti T.N., Holding C., Weedon H., Atkins G.J., Zannetino A., Ahern M.J., Coleman M., Roberts-Thomson P.J., Kraan M., Tak P.P. and Smith M.D. (2003). Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 42, 123-134.
33. Hofbauer L.C., Khosla S., Dunstan C., Lacey D.L., Boyle W. and Riggs B.L. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Min. Res. 15, 2-12.
34. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L. and Khosla S. (1999). Interleukin-1β and tumor necrosis factor-α but not interleukin-6, stimulatle osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25, 255-259.
35. Hollberg K., Hultenby K., Hayman A., Cox T. and Andersson G. (2002). Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp. Cell Res. 279, 227-238.
36. Hughes A.E., Ralston S.H. and Marken J. (2000). Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genet. 24, 45-48.
37. Hunter S.J., Rosen C.J. and Gay C.V. (1991). In vitro resorptive activity of isolated chick osteoclasts: Effects of carbonic anhydrase inhibition. J. Bone Miner. Res. 6, 61-66.
38. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A. and Bravo R. (1997). Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Med. 3, 1285-1289.
39. Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurukai T., Tamura M., Takahashi N. and Suda T. (1996). Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137, 2187-2190.
40. Kartsogiannis V., Zhou H., Horwood N.J., Thomas R.J., Hards D.K., Quinn J.M., Niforas P., Ng K.W., Martin T.J. and Gillespie M.T. (1999). Localization of RANKL (receptor activator of NF-κB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25, 525-534.
41. Kim H.H., Lee D.E., Shin J.N., Lee Y.S., Jeon Y.M., Chung C.H., Ni J., Kwon B.S. and Lee Z.H. (1999). Receptor activator of NF-κB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett. 443, 297-302.
42. Kitazawa R., Kitazawa S. and Maeda S. (1999). Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim. Biophys. Acta 1445, 134-141.
43. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K. and Shima N. (2000). TNF-α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191, 275-286.
44. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J. and Penninger J.M. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.
45. Kornak U., Bosl M.R. and Kubisch C. (1999). Complete genomic structure of the CLCN6 and CLCN7 putative chloride channel genes. Biochim. Biophys Acta. 1447, 100-106.
46. Kornak U., Kasper D., Bosl M.R., Kaiser E., Schweizer M., Schulz A., Friedrich W., Delling G. and Jentsch T.J. (2001). Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104, 205-215.
47. Koseki T., Gao Y., Okahashi N., Murase Y., Tsujisawa T., Sato T., Yamato K. and Nishihara T. (2002). Role of TGF-β family in osteoclastogenesis induced by RANKL. Cell Signal. 14, 31-36.
48. Kurihara N., Chenu C., Miller M., Civin C. and Roodman G.D. (1990). Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology 126, 2733-2741.
49. Kudo O., Fujikawa Y., Itonaga I., Sabokbar A., Torisu T. and Athanasou N.A. (2002). Proinflammatory cytokine (TNFα) induction of human osteoclast formation. J. Pathol. 198,220-227.
50. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y. and Athanasou N.A. (2003). Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32, 1-7.
51. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G, Guo J., Delaney J and Boyle W.J. (1998). Osteoprotegerin ligand in a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
52. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P. and Teitelbau S.L. (2000). TNFα induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488.
53. Langdahl B.L., Carstens M., Stenkjaer L. and Eriksen E.F. (2002). Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J. Bone Miner. Res. 17, 1245-1255.
54. Li X., Pilbeam C.C., Pan L., Breyer R.M. and Raisz L.G. (2002). Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 30, 567-573.
55. Li Y.P., Chen W., Liang Y., Li E. and Stashenko P. (1999). Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat. Genet. 23, 447-451.
56. Lindberg M.K., Erlandsson M., Alatalo S.L., Windahl S., Andersson G., Halleen J.M., Carlsten H., Gustafsson J.A. and Ohlsson C. (2001). Estrogen receptor-α, but not estrogen receptor-β, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-κB ligand) ratio and serum interleukin-6 in male mice. J Endocrinol. 171, 425-433.
57. Liu F., Hata A, Baker J., Doody J., Carcamo J., Harland R.M. and Massague J. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 381, 620-623.
58. Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., Morony S., Capparelli C., Van G. and Kaufman S. (1999). TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024.
59. Lopez-Rovira T., Chalaux E., Rosa J.L., Bartons R. and Ventura F. (2000). Interaction and functional cooperation of NF-κB with Smads. J. Biol. Chem. 275, 28937-28946.
60. Lubberts E., Van Den Bersselaar L., Oppers-Walgreen B., Schwarzenberger P., Coenen-De Roo C.J., Kolls J.K., Joosten L.A. and Van Den Berg W.B. (2003). IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of receptor activator of NF-κB ligand/osteoprotegerin balance. J. Immunol. 170, 2655-2662.
61. Madyastha P.R., Yang S., Ries W.L and Key L.L. Jr. (2000). IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production. J. Interferon Cytokine Res. 20, 645-652.
62. Marie P.J., Hott M., Launay J.M., Graulet A.M. and Gueris J. (1993). In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic postmeneopausal women: Relationship with cell proliferation. J. Clin. Endocrinol. Metab. 77, 824-830.
63. Mercurio F. and Manning A.M. (1999). Multiple signals converging on NF-κB. Curr. Opin Cell Biol. 11, 226-232.
64. +-adenosine triphosphatase in a Japanese patient with infantile malignant osteopetrosis. Bone 30, 436-439.
65. Miyazono K., Kusanagi K. and Inoue H. (2001). Divergence and Convergence of TGF-β/BMP Signaling. J. Cell Physiol. 18, 265-276.
66. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., Sato Y., Nakagawa N., Yasuda H., Mochizuki S. Gomibuchi T., Yano K., Shima N., Washida N., Tsuda E., Morinaga T., Higashio K. and Ozawa H. (1998). Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys. Res. Commun. 247, 610-615.
67. Murakami T., Yamamoto M., Ono K., Nishikawa M., Nagata N., Motoyoshi K. and Akatsu T. (1998). Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biophys. Res. Commun. 252, 747-752.
68. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H. and Sakai H. (2000). Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275, 768-775.
69. Neeck G., Renkawitz R. and Eggert M. (2002). Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis. Cytokines Cell. Mol. Ther. 7, 61-69.
70. Nesbitt S.A. and Horton M.A. (1997). Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 27, 266-269.
71. Onyia J.E, Libermann T.A., Bidwell J., Arnold D., Tu Y., McClelland P. and Hock J.M. (1997). Parathyroid hormone (1-34)-mediated interleukin-6 induction. J. Cell Biochem. 67, 265-274.
72. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S. and Marshak D.R. (1999). Multilineae potential of adult human mesenchymal stem cells. Science 284, 143-147.
73. Quinn J.M., Itoh K., Udagawa N., Hausler K., Yasuda H., Shima N., Mizuno A., Higashio K., Takahashi N., Suda T., Martin T.J. and Gillespi M.T. (2001). Transforming growth factor β affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16, 1787-1794.
74. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., Turk B., Pietschmann P., Woloszczuk W., Haralambous S., Kollias G., Steiner G., Smolen J.S. and Schett G. (2000). Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46, 785-792.
75. Ridderstad A., Abedi-Valugerdi M. and Moller E. (1991). Cytokines in rheumatoid arthritis. Ann. Med. 23, 219-223.
76. Romas E., Sims N.A., Hards D.K., Lindsay M., Quinn J.W., Ryan P.F., Dunstan C.R., Martin T.J. and Gillespie M.T. (2002). Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161, 1419-1427.
77. Ross F.P., Chappel J., Alvarez J.I., Sander D., Butler W.T., Farach-Carson M.C., Mintz K.A., Robey P.G., Teitelbaum S.L. and Cheresh D.A. (1993). Interaction between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alphavbeta3 potentiate bone resorption. J. Biol. Chem. 268, 9901-9907.
78. Roux S., Pichaud F., Quinn J., Lalande A., Morieux C., Jullienne A and de Vernejoul M.C. (1997). Effects of prostaglandins on human hematopoietic osteoclast precursors. Endocrinology 138, 1476-1482.
79. Sabokbar A., Kudo O. and Athanasou N.A. (2003). Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J. Orthop. Res. 21, 73-80.
80. Saika M., Inoue D., Kido S. and Matsumoto T. (2001). 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 142, 2205-2212.
81. Salo J., Lehenkari P., Metsikko K. and Vanananen H.K. (1997). Removal of osteoclast bone resopriton products by transcytosis. Science 276, 270-273.
82. Sasaki N., Kusano E., Ando Y., Yano K., Tsuda E. and Asano Y. (2001). Glucocorticoid decreases circulating osteoprotegerin (OPG): Possible mechanism for glucocorticoid induced osteoporosis. Nephrol. Dial. Transplant. 16, 479-782.
83. Schlesinger P.H., Blair H.C., Teitelbaum S.L. and Edwards J.C. (1997). Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J. Biol. Chem. 272, 18636-18643.
84. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P. and Boyle W.J. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.
85. Smith A.N., Skaug J., Choate K.A., Nayir A., Bakkaloglu A., Ozen S., Hulton S.A., Sanjad S.A., Al-Sabban E.A., Lifton R.P., Scherer S.W. and Karet F.E. (2000). Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. Nature Genet. 26, 71-75.
86. +ATPase-ATPase α-subunit gene. J. Biol Chem. 276, 2382-42388.
87. Soriano P., Montgomery C., Geske R and Bradley A. (1991). Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702.
88. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P. and Pacifici R. (2001). Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276, 8836-8840.
89. Suda T., Udagawa N., Nakamura J., Miyaura C. and Takahashi N. (1995). Modulation of osteoclast differentiation by local factors. Bone 17, (Suppl 2) 87S-91S.
90. Suda T., Ueno Y., Fujii K. and Shinki T. (2003). Vitamin D and bone. J Cell Biochem. 88, 259-266.
91. Takahashi N., Idagawa N., Tamaka S., Murakami H., Owan I., Tamura I. and Suda T. (1994). Postmitotic osteoclast precursors are mononuclear cells which express macrophage-associated phenotypes. Devel. Biol. 163, 212-221.
92. Tani-Ishii N., Tsunoda A., Teranaka T. and Umemoto T. (1999). Autocrine regulation of osteoclast formation and bone resorption by IL-1a and TNFα. J. Dental Res. 78, 1617-1623.
93. Tanaka S., Takahashi N., Udagawa N., Tamura T., Akatsu T., Stanly E.R., Kurokawa T. and Suda T. (1993). Macrophage colony stimulating factor is indispensible for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91, 257-265.
94. Tanaka S., Amling M., Neff L., Peyman A., Uhlmann E., Levy J.B. and Baron R. (1996). c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383, 528-531.
95. Taylor P.C. (2003). Anti-TNFα therapy for rheumatoid arthritis: An update. Intern Med. 42, 15-20.
96. Teti A., Blair H.C., Teitelbaum S.L., Kahn A.J., Koziol C.M., Konsek J, Zambonin-Zallone A. and Schlesinger P.H. (1989). Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J. Clin Invest. 83, 227-233.
97. Tezuka K., Tezuka Y., Maejima A., Sato T., Nemoto K., Kamioka H., Hakeda Y. and Kumegawa M. (1994). Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 26, 1106-1009.
98. Thirunavukkarasu K., Miles R.R., Halladay D.L., Yang X., Galvin R.J., Chandrasekhar S., Martin T.J. and Onyia J.E. (2001). Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-β (TGF-β). Mapping of the OPG promoter region that mediates TGF-β effects. J. Biol. Chem. 276, 36241-36250.
99. Tondravi M.M., McKercher S.R., Anderson K., Erdmann J.M., Quiroz M., Maki R. and Teitelbaum S.L. (1997). Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 385, 81-84.
100. Toraldo G., Roggia C., Qian W.P., Pacifici R. and Weitzmann M.N. (2003). IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor-κB ligand and tumor necrosis factor-α from T cells. Proc. Natl. Acad. Sci. USA 100, 125-130.
101. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T. and Higashio K. (1997). Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142.
102. Walker D.G. (1973). Osteopetrosis cured by temporary parabiosis. Science 180, 875.
103. Walker D.G. (1975). Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 190, 784-785.
104. Whyte M.P., Obrecht S.E., Finnegan P.M., Jones J.L., Podgomik M.N., McAlister W.H. and Mumm S. (2002). Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347, 175-184.
105. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y. and Choi Y. (1997). TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-21594.
106. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H. and Choi Y. (1999). TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4, 1041-1049.
107. Wuyts W., Van Wessenbeeck L., Morales-Piga A., Ralston S., Hocking L., Vanhoenacker F., Westhovens R., Verbruggen L., Anderson D., Hughes A. and Van Hul W. (2001). Evaluation of the role of RNAK and OPG genes in Paget's disease of bone. Bone 28, 104-107.
108. Yang S., Ries W.L. and Key L.L Jr. (1999). Superoxide generation in transformed B-lymphocytes from patients with severe, malignant osteopetrosis. Mol. Cell Biochem. 199, 15-24.
109. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., Toriyabe T., Kawabata M., Miyazono K. and Kato S. (1999). Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283, 1317-1321.
110. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., Ikeda K., Higashio K. and Yamada Y. (1999). Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14, 518-527.
111. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., Sudo T., Shultz L.D. and Nishikawa S. (1990). The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1345, 442-444.
112. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T. and Higashio K. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337.
113. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N. and O'Keefe R.J. (2002). Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109, 1405-1415.
114. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., Filipowicz-Sosnowska A., Pazdur J., Szechinski J., Kowalczewski J., Rell-Bakalarska M. nd Maslinski W. (2002). High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor a treatment. Arthritis Rheum. 46, 1744-1753.